PharmaCyte Biotech, Inc. (21)
Browse by Contract Category
Contracts
-
Release Agreement, dated October 12, 2022, by and between PharmaCyte Biotech, Inc. and Gerald W. Crabtree
(Filed With SEC on October 14, 2022)
-
Separation, Consulting and Release Agreement, dated October 6, 2022, by and between PharmaCyte Biotech, Inc. and Kenneth L. Waggoner
(Filed With SEC on October 7, 2022)
-
Form of Director Offer Letter
(Filed With SEC on August 16, 2022)
-
Cooperation Agreement dated August 15, 2022, by and between PharmaCyte Biotech, Inc. and Iroquois Master Fund Ltd. and its affiliates
(Filed With SEC on August 16, 2022)
-
PharmaCyte Biotech, Inc. 2021 Equity Incentive Plan
(Filed With SEC on July 28, 2022)
-
Amended and Restated Executive Compensation Agreement, dated May 8, 2022, between Carlos A. Trujillo and the Company
(Filed With SEC on July 28, 2022)
-
Amended and Restated Executive Compensation Agreement, dated May 8, 2022, between Kenneth L. Waggoner and the Company
(Filed With SEC on July 28, 2022)
-
Description of Securities
(Filed With SEC on July 28, 2022)
-
Form of Placement Agent Common Stock Purchase Warrant
(Filed With SEC on August 23, 2021)
-
Securities Purchase Agreement, dated as of August 19, 2021
(Filed With SEC on August 23, 2021)
-
Form of Series A Warrant Common Stock Purchase Warrant
(Filed With SEC on August 23, 2021)
-
Form of Pre-Funded Common Stock Purchase Warrant
(Filed With SEC on August 23, 2021)
-
Form of Underwriters Warrant
(Filed With SEC on August 12, 2021)
-
Form of Pre-funded Warrant
(Filed With SEC on August 12, 2021)
-
Form of Common Warrant
(Filed With SEC on August 12, 2021)
-
Underwriting Agreement, dated as of August 9, 2021
(Filed With SEC on August 12, 2021)
-
Description of Securities
(Filed With SEC on August 10, 2021)
-
Amendment No. 3, dated as of October 14, 2020, to Executive Compensation Agreement between Gerald W. Crabtree and the Company
(Filed With SEC on October 16, 2020)
-
Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc. and Silver Rock Associates, Inc., dated May 4, 2020
(Filed With SEC on September 11, 2020)
-
Amendment No. 1 to Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc. and Silver Rock Associates, Inc., dated July 15, 2020
(Filed With SEC on September 11, 2020)
-
Share Subscription Agreement between the Company and the Investor dated January 17, 2020
(Filed With SEC on January 21, 2020)
